Composition for the prevention or treatment of TNF-related diseases containing a novel derivative as an active ingredient, and method for inhibiting TNF activity using the same.

Abstract

To provide a composition for preventing, alleviating or treating TNF-related diseases, containing a 4-benzopyranone derivative and a pharmaceutically acceptable salt, solvate, racemate or stereoisomer thereof as an active ingredient; and a method for treating TNF-related diseases using the composition, a reagent composition for inhibiting TNF, and a method for inhibiting TNF.SOLUTION: The invention relates to: a composition for preventing, alleviating or treating TNF-related diseases, containing a 4-benzopyranone derivative and a pharmaceutically acceptable salt, solvate, racemate or stereoisomer thereof as an active ingredient; and a method for treating TNF-related diseases using the composition, a reagent composition for inhibiting TNF, and a method for inhibiting TNF. The composition can be orally administered so as not to cause injection side effects and immunological tolerance, and can effectively inhibit TNF activity by directly binding to TNF while facilitating co-administering with a conventional oral preparation and dosage control.SELECTED DRAWING: Figure 5a

Claims

1. A pharmaceutical composition for the prevention or treatment of TNF-overexpression disease, wherein the TNF-overexpression disease is rheumatoid arthritis, and the pharmaceutical composition is characterized by comprising 2-(2,5-difluorophenyl)-3-carboxy-7-chloro-(4H)-4-benzopyranone or a pharmaceutically acceptable salt thereof.

2. The pharmaceutical composition for the prevention or treatment of TNF-overexpression disease according to claim 1, further comprising a drug.

3. The aforementioned drugs include methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, bucillamine, cyclosporine, tacrolimus, azathioprine, cyclophosphamide, mizoribine, penicillamine, oral gold preparations, antimalarial agents, 6-mercaptopurine, indomethacin, naproxen, sulindac, diclofenac, aceclofenac, mefenamic acid, aspirin, fenoprofen, sarsalate, piroxicam, etodolac, flurbiprofen, ibuprofen, loxoprofen, nabumetone, lonazolac, meloxicam, and fenbufen. Indoprofen, ketrolactromethamine, indoprofen, ketoprofen, suprofen, carprofen, tiaprofenic acid, flufenamic acid, ebuselene, felbinac, tolmetin, flunixin, celecoxib, lofecoxib, hydrocortisone, cortisone, prednisolone, methylprednisolone, triamcinolone, betamethasone, dexamethasone, fludrocortisone, entocort, 5-aminosalicylic acid, 6-thioguanine, cytarabine, 5-fluorouracil, dacarbazine, mechloretamine, thiotepa, chlorambucil, melfa Lan, Carmustine, Lomustine, Busulfan, Sestrin 2, Withaferin A, Cerastrol, Quercetin, Luteolin, Curcumin, Metformin, Dibromomannitol, GR270773, Pentoxifylline, N-Acetylcysteine, Melatonin, Resveratrol, Mesalamine, Single-chain fatty acids, Glutamine, Gemfibrozil, Retinoids, Hydroxyurea, Trihydroxyisoflavones, Deoxykaemperol, Kaempferol, Gingerol, Caffeic acid, Cyanidin, Cryptotancinone, Deguerin, Delphinidin, Equol Fisetin, Myricetin, Procyanidin B2, Metronidazole, Ciprofloxacin, Niclosamide, Thiabendazole, Imipenem-Cilastatin, Fluoroquinolone, Tofacitinib, Glybride, Rolipram, Doxycycline, VX-166, zVAD, L-97-1, ISO-1, Tauroursodeoxycholic acid, HK-156, A-285222, CP-0127, Bis-N-Norgliovictin, Aurintricarboxylic acid, Chloromidine, Ouabain, Terazosin, Prazosin, Tranilast,Apremilast, monobenzone, phenazopyridine, 546C88, NOX-100, gabexate mesylate, urinastatin, somatostatin, octreotide, IKK inhibitor, caspase inhibitor, TAK-242, erythritol, ki16425, camptothecin, phenethyl caffeate, sulforaphane, Tim-3, BN-52021, BB-882, TCV-309, CT-400, ethyl pyruvate, hemin, CORM-2, tancinone IIA sulfonate, nicotine, EGCG, isorhamnetin-3-O-galactoside, persica Phosphorus, catechin, carbenoxolone, glycyrrhizin, emodin-6-O-b-D-glucoside, acteoside, forcitoside B, rosmarinic acid, chlorogenic acid, infliximene, cilostazol, clopidogrel, sarpogrelate, dorotrecodin α, carbamazepine, chloroquine, anakinra, tocilizumab, LMT-28, 1-(3-dimethylaminopropyl)-3-ethylurea, gp130Fc, β-arrestin 2, IL-30, diacelein, secukinumab, ustekinumab, ixekizumab, thalidomide, adalimumab, inflixima Pravastatin, Atorvastatin, Rosuvastatin, Simvastatin, Losartan, Telmisartan, Hydrochlorothiazide, Furosemide, Propranolol, Metoprolol, Captopril, Amlodipine, Clonidine, Methyldopa, Minoxidil, Streptozotocin, Mitomycin, Cisplatin, Daunorubicin, Doxorubicin, Dactinomycin, Bleomycin, Mitramycin, Anthramycin, Calicaemicin, Duocalmycin, Taxol, Docetaxel, Cytochalasin B, Gramicidin D, Ethidium Bromide, Emeth Mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicine, dihydroxyanthracendione, mitoxantrone, mitramycin, actinomycin D, 1-dehydrotestosterone, procaine, tetracaine, lidocaine, propranolol, tamoxifen, bazedoxifen, puromycin, anethole trithione, nivolumab, pembrolizumab, ipilimumab, atezolizumab, α-galactosylceramide, SRT3025, DTA-1, IL-7, IL-2, IL-15, CXCL1, ATRA,A pharmaceutical composition for the prevention or treatment of TNF-overexpression disease according to claim 2, characterized by being selected from the group consisting of gemcitabine, carboplatin, NCX-4016, CDDO-Me, sunitinib, zoledronic acid, astragalus polysaccharide, rituximab, Imuran, abatacept, GW9662, rosiglitazone, Y-27632, and alefacept.

4. A functional food composition for the prevention or improvement of TNF-overexpression disease, wherein the TNF-overexpression disease is rheumatoid arthritis, and the functional food composition is characterized by containing 2-(2,5-difluorophenyl)-3-carboxy-7-chloro-(4H)-4-benzopyranone or a pharmaceutically acceptable salt thereof as an active ingredient.

5. A reagent composition for inhibiting TNF activity in vitro in TNF-overexpression diseases, wherein the TNF-overexpression disease is rheumatoid arthritis, and the reagent composition is characterized by containing 2-(2,5-difluorophenyl)-3-carboxy-7-chloro-(4H)-4-benzopyranone or a pharmaceutically acceptable salt thereof as an active ingredient.

Images